AU Patent

AU2023393624A1 — Anti-ilt7 binding agents for the treatment and prevention of myositis

Assigned to Viela Bio Inc · Expires 2025-05-15 · 1y expired

What this patent protects

The present disclosure is related to compositions and methods of treating diseases (e.g., myositis diseases and disorders) in a subject in need thereof using anti-ILT7 antibodies or antigen-binding fragments thereof.

USPTO Abstract

The present disclosure is related to compositions and methods of treating diseases (e.g., myositis diseases and disorders) in a subject in need thereof using anti-ILT7 antibodies or antigen-binding fragments thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023393624A1
Jurisdiction
AU
Classification
—
Expires
2025-05-15
Drug substance claim
No
Drug product claim
No
Assignee
Viela Bio Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.